Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study-Reference-Cited by-同舟云学术

Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study

Published:2021-06 Issue:6 Volume:84 Page:1554-1561
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Boull Christina L.,Gardeen Samantha,Abdali Talal,Li Edward,Potts Jolee,Rubin Nathan,Carlberg Valerie M.,Gupta Deepti,Hunt Raegan,Luu Minnelly,Maguiness Sheilagh M.,Moertel Christopher L.,Song Hannah,Vivar Karina L.,Coughlin Carrie,Huang Jennifer T.,Lara-Corrales Irene

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Dermatology

Reference40 articles.

1. The clinical development of MEK inhibitors;Zhao;Nat Rev Clin Oncol,2014

2. Analysis of dermatologic events in vemurafenib treated patients with melanoma;Lacouture;Oncologist,2013

3. Phase II study of the MEK1/MEK2 inhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor;Kim;J Clin Oncol,2013

4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial;Long;Lancet,2015

5. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study;McArthur;Lancet Oncol,2014

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature;Supportive Care in Cancer;2024-08-23

2. A rare cutaneous infection with Mycobacterium chelonae in a pediatric patient treated with trametinib for KRAS‐mutated diffuse glioma;Pediatric Dermatology;2024-08-15

3. Consensus of the Taiwanese dermatological association and Taiwan Lung Cancer Society on the prevention and management of tyrosine kinase inhibitor-related skin toxicities in patients with non-small cell lung cancer: An updated version incorporating Taiwanese treatment experience;Journal of the Formosan Medical Association;2024-08

4. Outcome Measurement Instruments Used to Evaluate Dermatologic Adverse Events in Cancer Trials;JAMA Dermatology;2024-06-01

5. Dabrafenib for Pilocytic Astrocytoma With BRAF V599ins;JCO Precision Oncology;2024-05